Angiotensin AT₂ receptor stimulation inhibits early renal inflammation in renovascular hypertension

Hypertension. 2011 Feb;57(2):308-13. doi: 10.1161/HYPERTENSIONAHA.110.164202. Epub 2010 Dec 28.

Abstract

Angiotensin II type 2 receptor (AT₂R) counteracts most effects of angiotensin II type 1 receptor (AT(1)R). We hypothesized that direct AT₂R stimulation reduces renal production of the inflammatory cytokines tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and transforming growth factor-β1 (TGF-β1) and enhances the production of nitric oxide (NO) and cyclic guanosine 3',5'-monophosphate (cGMP) in the clipped kidney of 2-kidney, 1-clip (2K1C) hypertension rat model. We used Sprague-Dawley rats to evaluate changes in renal interstitial fluid recovery levels of TNF-α, IL-6, NO, and cGMP; renal expression of AT₁R, AT₂R, TGF-β1, TNF-α, and IL-6 in sham and 2K1C rats treated for 4 days with vehicle, AT₂R agonist compound 21 (C21), or AT₂R antagonist PD123319 (PD), alone and combined (n=6, each group). Systolic blood pressure increased significantly in 2K1C and was not influenced by any treatment. Clipped kidneys showed significant increases in renal expression of AT₁R, AT₂R, TNF-α, IL-6, TGF-β1 and decreases in NO and cGMP levels. These factors were not influenced by PD treatment. In contrast, C21 caused significant decrease in renal TNF-α, IL-6, TGF-β1 and an increase in NO and cGMP levels. Combined C21 and PD treatment partially reversed the observed C21 effects. Compared to sham, there were no significant changes in TNF-α, IL-6, TGF-β1, NO, or cGMP in the nonclipped kidneys of 2K1C animals. We conclude that direct AT₂R stimulation reduces early renal inflammatory responses and improves production of NO and cGMP in renovascular hypertension independent of blood pressure reduction.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Angiotensin II Type 2 Receptor Blockers / pharmacology
  • Animals
  • Blood Pressure
  • Blotting, Western
  • Body Weight
  • Cyclic GMP / metabolism
  • Gene Expression
  • Hypertension, Renovascular / genetics
  • Hypertension, Renovascular / metabolism*
  • Hypertension, Renovascular / physiopathology
  • Imidazoles / pharmacology
  • Inflammation / genetics
  • Inflammation / metabolism*
  • Inflammation / pathology
  • Interleukin-6 / genetics
  • Interleukin-6 / metabolism
  • Kidney / drug effects
  • Kidney / metabolism*
  • Kidney / pathology
  • Male
  • Nitric Oxide / metabolism
  • Organ Size
  • Pyridines / pharmacology
  • Rats
  • Rats, Sprague-Dawley
  • Receptor, Angiotensin, Type 1 / genetics
  • Receptor, Angiotensin, Type 1 / metabolism
  • Receptor, Angiotensin, Type 2 / agonists
  • Receptor, Angiotensin, Type 2 / genetics
  • Receptor, Angiotensin, Type 2 / metabolism*
  • Reverse Transcriptase Polymerase Chain Reaction
  • Sulfonamides / pharmacology
  • Thiophenes / pharmacology
  • Transforming Growth Factor beta1 / genetics
  • Transforming Growth Factor beta1 / metabolism
  • Tumor Necrosis Factor-alpha / genetics
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • Angiotensin II Type 2 Receptor Blockers
  • Imidazoles
  • Interleukin-6
  • N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-isobutylthiophene-2-sulfonamide
  • Pyridines
  • Receptor, Angiotensin, Type 1
  • Receptor, Angiotensin, Type 2
  • Sulfonamides
  • Thiophenes
  • Transforming Growth Factor beta1
  • Tumor Necrosis Factor-alpha
  • PD 123319
  • Nitric Oxide
  • Cyclic GMP